These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 17465029)
1. Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. Wakamatsu M; Ishii A; Ukai Y; Sakagami J; Iwata S; Ono M; Matsumoto K; Nakamura A; Tada N; Kobayashi K; Iwatsubo T; Yoshimoto M J Neurosci Res; 2007 Jun; 85(8):1819-25. PubMed ID: 17465029 [TBL] [Abstract][Full Text] [Related]
2. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Schell H; Hasegawa T; Neumann M; Kahle PJ Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424 [TBL] [Abstract][Full Text] [Related]
3. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. Rockenstein E; Schwach G; Ingolic E; Adame A; Crews L; Mante M; Pfragner R; Schreiner E; Windisch M; Masliah E J Neurosci Res; 2005 Apr; 80(2):247-59. PubMed ID: 15765523 [TBL] [Abstract][Full Text] [Related]
4. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678 [TBL] [Abstract][Full Text] [Related]
6. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Wakamatsu M; Ishii A; Iwata S; Sakagami J; Ukai Y; Ono M; Kanbe D; Muramatsu S; Kobayashi K; Iwatsubo T; Yoshimoto M Neurobiol Aging; 2008 Apr; 29(4):574-85. PubMed ID: 17174013 [TBL] [Abstract][Full Text] [Related]
7. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360 [TBL] [Abstract][Full Text] [Related]
8. Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein. Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL J Neurochem; 2006 Feb; 96(4):950-9. PubMed ID: 16412098 [TBL] [Abstract][Full Text] [Related]
9. Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology. Ikeda M; Kawarabayashi T; Harigaya Y; Sasaki A; Yamada S; Matsubara E; Murakami T; Tanaka Y; Kurata T; Wuhua X; Ueda K; Kuribara H; Ikarashi Y; Nakazato Y; Okamoto K; Abe K; Shoji M Brain Res; 2009 Jan; 1250():232-41. PubMed ID: 18992718 [TBL] [Abstract][Full Text] [Related]
10. Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice. Tanji K; Mori F; Mimura J; Itoh K; Kakita A; Takahashi H; Wakabayashi K Acta Neuropathol; 2010 Aug; 120(2):145-54. PubMed ID: 20339856 [TBL] [Abstract][Full Text] [Related]
11. Prosurvival effect of human wild-type alpha-synuclein on MPTP-induced toxicity to central but not peripheral catecholaminergic neurons isolated from transgenic mice. Pérez-Sánchez F; Milán M; Buendía P; Cano-Jaimez M; Ambrosio S; Rosenthal A; Fariñas I Neuroscience; 2010 May; 167(2):261-76. PubMed ID: 20156526 [TBL] [Abstract][Full Text] [Related]
12. α-synuclein phosphorylation and truncation are normal events in the adult human brain. Muntané G; Ferrer I; Martinez-Vicente M Neuroscience; 2012 Jan; 200():106-19. PubMed ID: 22079575 [TBL] [Abstract][Full Text] [Related]
13. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. Ono K; Ikemoto M; Kawarabayashi T; Ikeda M; Nishinakagawa T; Hosokawa M; Shoji M; Takahashi M; Nakashima M Parkinsonism Relat Disord; 2009 Nov; 15(9):649-54. PubMed ID: 19345133 [TBL] [Abstract][Full Text] [Related]
14. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Chu Y; Kordower JH Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279 [TBL] [Abstract][Full Text] [Related]
15. G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression. Liu P; Wang X; Gao N; Zhu H; Dai X; Xu Y; Ma C; Huang L; Liu Y; Qin C Brain Res; 2010 Jan; 1307():134-41. PubMed ID: 19852948 [TBL] [Abstract][Full Text] [Related]
16. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459 [TBL] [Abstract][Full Text] [Related]
17. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain. Bergeron M; Motter R; Tanaka P; Fauss D; Babcock M; Chiou SS; Nelson S; San Pablo F; Anderson JP Neuroscience; 2014 Jan; 256():72-82. PubMed ID: 24128992 [TBL] [Abstract][Full Text] [Related]